Vanda Pharmaceuticals Inc. (VNDA) stock
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
Earnings
Vanda Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Vanda Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 10, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 28, 2026after the close | $69.80M | +24.1% | -$0.37 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026after the close | $51.70M | +3.3% | -$0.82 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 11, 2026after the close | $57.20M | +7.5% | -$2.39 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025after the close | $56.26M | +17.9% | -$0.38 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025before the open | $52.60M | +4.2% | -$0.46 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025after the close | $50.04M | +5.3% | -$0.50 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 13, 2025after the close | $53.20M | +17.4% | -$0.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $47.70M | +22.9% | -$0.09 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $50.50M | +9.5% | -$0.08 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $47.50M | -24.0% | -$0.07 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 7, 2024after the close | $45.30M | -29.8% | -$0.04 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | $38.80M | -40.6% | $0.00 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 27, 2023after the close | $46.10M | -28.4% | $0.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023after the close | $62.50M | +3.8% | $0.06 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 8, 2023after the close | $64.50M | -5.1% | $0.12 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022after the close | $65.30M | -6.8% | $0.06 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022after the close | $64.40M | – | $0.05 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $60.20M | – | -$0.11 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022after the close | $68.00M | – | $0.12 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021after the close | $70.10M | – | $0.14 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 10, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 28, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Vanda Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total revenue | FY2026 | $240.00M | – | New | Oct 28, 2026 |
| Total revenues | FY2026 | $240.00M – $290.00M | $230.00M – $260.00M | Raised | May 6, 2026 |
| Fanapt ® net product sales | FY2026 | $150.00M – $170.00M | – | New | Feb 11, 2026 |
| Other net product sales | FY2026 | $80.00M – $90.00M | – | Lowered | Feb 11, 2026 |
Guidance vs results
The last range Vanda Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $210.00M – $230.00M | $216.10MΣ4Q | Within range |
Guidance history
Every forecast Vanda Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 28, 2026 | total revenue | FY2026 | $240.00M | New |
| May 6, 2026 | Total revenues | FY2026 | $240.00M – $290.00M | Raised |
| Feb 11, 2026 | Fanapt ® net product sales | FY2026 | $150.00M – $170.00M | New |
| Feb 11, 2026 | Other net product sales | FY2026 | $80.00M – $90.00M | Lowered |
| Feb 11, 2026 | Total revenues | FY2026 | $230.00M – $260.00M | New |
| Oct 29, 2025 | Year-end 2025 Cash | FY2025 | $260.00M – $290.00M | New |
| Oct 29, 2025 | Total revenues | FY2025 | $210.00M – $230.00M | New |
| Jul 31, 2025 | Year-end 2025 Cash | FY2025 | $280.00M – $320.00M | Reaffirmed |
| Jul 31, 2025 | Total revenues | FY2025 | $210.00M – $250.00M | Reaffirmed |
| May 7, 2025 | Year-end 2025 Cash | FY2025 | $280.00M – $320.00M | New |
| May 7, 2025 | Total revenues | FY2025 | $210.00M – $250.00M | Reaffirmed |
| Feb 13, 2025 | Total revenues | FY2025 | $210.00M – $250.00M | New |
| Nov 6, 2024 | Year-end 2024 Cash | FY2024 | $370.00M – $390.00M | Raised |
| Nov 6, 2024 | Total revenues | FY2024 | $190.00M – $210.00M | Raised |
| Jul 31, 2024 | Year-end 2024 Cash | FY2024 | $360.00M – $390.00M | New |
| Jul 31, 2024 | Total revenues | FY2024 | $180.00M – $210.00M | New |
| Nov 2, 2022 | Year-end 2022 Cash | FY2022 | $450.00M | Raised |
| Nov 2, 2022 | Total revenues | FY2022 | $240.00M – $270.00M | Lowered |
| Nov 2, 2022 | HETLIOZ ® net product sales | FY2022 | $150.00M – $170.00M | Lowered |
| Nov 2, 2022 | Fanapt ® net product sales | FY2022 | $90.00M – $100.00M | Lowered |
| Aug 3, 2022 | Total revenues | FY2022 | $240.00M – $280.00M | Reaffirmed |
| May 5, 2022 | Total revenues | FY2022 | $240.00M – $280.00M | Raised |
| Feb 23, 2022 | Year-end 2022 Cash | FY2022 | $440.00M | New |
| Feb 23, 2022 | Total revenues | FY2022 | $240.00M – $280.00M | New |
| Feb 23, 2022 | HETLIOZ ® net product sales | FY2022 | $150.00M – $180.00M | Lowered |
| Feb 23, 2022 | Fanapt ® net product sales | FY2022 | $90.00M – $100.00M | Lowered |
| Nov 3, 2021 | Total revenues | FY2021 | $260.00M – $290.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Vanda Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- News
- News
- News
- News
- Results
- News
- Results
- Results
- Results
- Results
See a number that looks wrong?